 Adagio Therapeutics Inc NASDAQ: ADGI announced that the independent data monitoring committee IDMC has recommended expanding the ADG20 EVADE Phase 23 trial for COVID-19. The IDMC has supported the expansion of Phase 3 trial enrollment to include adolescents and pregnant or nursing women and decrease the protocol-specified, post-injection monitoring time. 